Disclosure Plus

CoAsia CM Decides on 5-for-1 Stock Consolidation

Park Sun-Yeop
2026-06-26 13:32:17
[Edaily Reporter Park Sun-Yeop ] CoAsia CM(196450)announced on the 26th that it has decided to conduct a stock consolidation, changing the par value per share from 1,000 won to 5,000 won.
As a result of this stock consolidation, the total number of issued shares will decrease from 45,319,582 common shares to 9,063,916.
The company explained that the purpose of the stock consolidation is “to stabilize the stock price and enhance corporate value by maintaining an appropriate number of shares in circulation.”
This stock consolidation is not a capital reduction that decreases the company’s capital; rather, it is a stock consolidation method that preserves corporate value. Fractional shares (less than one share) will be settled in cash based on the closing price on the first day of trading of the new shares.
The stock consolidation proposal will be submitted to the Extraordinary General Meeting of Shareholders on August 6. The effective date for the new shares is August 11, and trading is scheduled to be suspended from August 7 through August 27. The new shares are scheduled to be listed on August 28.

Economy

Corporation

IT·Science

Economy

Electric Vehicles Are Already Dominated by Chinese Models; Semiconductor Supply Chains Are Also Being Reshaped at a Rapid Pace

“A professor from Peking University in China persistently asked questions and probed deeply into ‘hybrid bonding’ technology. He was very proactive.”Professor Yoo Hoe-jun of the Department of Electric…
2026-08-20 00:00:04

Corporation

"Just Enjoy the Barre Class for Now"... Viewori Targets the Wellness Crowd [Report]

On the afternoon of the 18th, at the Vuori pop-up store in Seongsu-dong, Seongdong-gu, Seoul, a different scene unfolded as I passed through the first and second floors—where clothes were displayed—an…
2026-08-19 15:40:50

IT·Science

Lundbeck Explores Other Indications for 'APB-A1'… "A Negative Sign, Even If Development Isn't Halted"

AprilBio Co.,Ltd.(397030)has decided to explore other indications for “APB-A1” (Lu AG22515), a technology it licensed to Lundbeck, after the compound failed to demonstrate the expected clinical effica…
2026-08-19 20:21:02